EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.

Learn the essential early warning signs of leukemia that are often dismissed as everyday ailments but could be indicators of ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.

This cancer-patient dad of three young kids is grateful for a "sci-fi" blood treatment advanced by Vanderbilt and oncologist Dr. Olalekan Oluwole.

Poor physical function correlated with outcomes among patients with non-Hodgkin lymphoma who underwent chimeric antigen receptor T-cell therapy, according to results of a retrospective cohort ...

The Leukemia and Lymphoma Society is hosting a fundraiser to support the research of cancers such as leukemia and lymphoma on April 3. The fundraiser’s ...

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and ...

SUV remains the most widely used PET parameter to evaluate NHLs because it is directly associated with lymphoma aggressiveness.

Despite multiple treatments for eczema and pityriasis alba, a child’s skin condition worsened until a biopsy revealed mycosis fungoides.

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.